Armed Cell Therapeutics acquires cell therapy pipeline from Lakefront Biotherapeutics NV
What happened
Armed Cell Therapeutics BV acquired Lakefront Biotherapeutics NV's early-stage cell therapy pipeline. The transaction includes an upfront payment of €8 million and potential milestone payments of up to $230 million, along with a low-single-digit royalty to Lakefront Biotherapeutics NV. The pipeline consists of multi-targeting and armed CAR-T constructs.
From manilatimes.net
Why it matters
The acquisition allows Armed Cell Therapeutics to independently advance the preclinical assets, which were originally based on technology from AboundBio. The sale offers Lakefront Biotherapeutics NV shareholders an opportunity to benefit from the future progress of the assets.
From manilatimes.net
Who's involved
- Paul StoffelsFounder of Armed Cell Therapeutics BV
- John MellorsFounder of Armed Cell Therapeutics BV
- companyCompany that acquired the early-stage cell therapy pipeline
- GalapagosBiotechnology company whose technology informed the acquired pipeline
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- companySpeculative
Armed Cell Therapeutics might see its revenue potential increase by acquiring the early-stage cell therapy pipeline
- John MellorsSpeculative
John Mellors might see changes in his professional contracts due to his role as a founder of Armed Cell Therapeutics
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Paul Stoffels
physician, medical researcher
Nothing else this week.